BONESUPPORT commenced trading on Nasdaq Stockholm following completion of its IPO, for which the final price was set at SEK 29/share (~US $3.31/share). Final proceeds after issue costs will be SEK 461MM (~$53.0MM).
BONESUPPORT markets CERAMENT injectable, drug-eluting bioceramic bone graft substitutes to treat bone voids. Funds will support U.S. and EU sales, collection of clinical data, product development, etc. In mid-2Q17, the company enrolled the first patient in the pivotal Investigational Device Exemption FORTIFY trial, “A Prospective, Randomized, Multicenter Controlled Trial of CERAMENT G as Part of Surgical Repair of Open Diaphyseal Tibial Fractures,” that is key to the company’s pursuit of U.S. approval for the product.
BONESUPPORT commenced trading on Nasdaq Stockholm following completion of its IPO, for which the final price was set at SEK 29/share (~US $3.31/share). Final proceeds after issue costs will be SEK 461MM (~$53.0MM).
BONESUPPORT markets CERAMENT injectable, drug-eluting bioceramic bone graft substitutes to treat bone voids. Funds will...
BONESUPPORT commenced trading on Nasdaq Stockholm following completion of its IPO, for which the final price was set at SEK 29/share (~US $3.31/share). Final proceeds after issue costs will be SEK 461MM (~$53.0MM).
BONESUPPORT markets CERAMENT injectable, drug-eluting bioceramic bone graft substitutes to treat bone voids. Funds will support U.S. and EU sales, collection of clinical data, product development, etc. In mid-2Q17, the company enrolled the first patient in the pivotal Investigational Device Exemption FORTIFY trial, “A Prospective, Randomized, Multicenter Controlled Trial of CERAMENT G as Part of Surgical Repair of Open Diaphyseal Tibial Fractures,” that is key to the company’s pursuit of U.S. approval for the product.
Copy to clipboard 
